文献速递外周动脉疾病主动脉疾病

VIABAHN VBX 覆膜支架治疗外周动脉疾病患者主髂动脉闭塞性病变的中期结局

Medium-Term Outcomes of Treatment with a VIABAHN VBX Covered Stent for Aortoiliac Occlusive Lesions in Patients with Peripheral Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2024-04-10

日本7中心回顾性分析71例患者共95例次VIABAHN VBX支架主髂动脉闭塞病变腔内治疗,中位随访36个月,3年一期通畅率91%、二期通畅率99%、免于靶病变血运重建92%、免于主要不良肢体事件98%,无大截肢,病变严重程度及严重钙化不影响通畅率。

要点

  • 主髂动脉闭塞病变使用VIABAHN VBX支架,3年一期通畅率91%、免于靶病变血运重建92%。
  • 中位随访36个月,无肢体需大截肢,3年免于主要不良肢体事件98%。

核心结论

  • VIABAHN VBX支架用于主髂动脉闭塞病变的中期结局可接受,不受病变严重程度和钙化影响。
  • 作者认为VIABAHN VBX可能适用于解剖复杂和/或严重钙化的主髂动脉闭塞性病变。

研究设计与样本

  • 回顾性研究,纳入2018年至2020年在日本7个中心接受VIABAHN VBX支架腔内治疗的主髂动脉病变的症状性患者。
  • 共71例患者、95例次腔内治疗操作。
  • 主要终点为一期通畅率和免于靶病变血运重建。

主要发现

  • 患者合并血脂异常53%、慢性肾脏病61%,22%患有慢性肢体威胁性缺血。
  • TASC Ⅱ分级:A级12例(17%)、B级12例(17%)、C级10例(14%)、D级37例(52%)。
  • 治疗病变严重钙化(360°)存在于31例(33%)。
  • 中位手术时间84(49-158)分钟,技术成功率100%。
  • 中位随访36(32-43)个月,VIABAHN VBX的3年一期通畅率和二期通畅率分别为91%和99%,3年免于靶病变血运重建92%,3年免于主要不良肢体事件98%,无肢体需大截肢。

临床怎么用

  • 作者认为VIABAHN VBX可能适用于解剖复杂和/或严重钙化的主髂动脉闭塞性病变。
  • 原文未据此给出其他临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular treatment (EVT) for aortoiliac (AI) occlusive lesions is now conducted worldwide, but there are challenges in EVT for complex AI lesions. The VIABAHN VBX (W.L. Gore & Associates, Flagstaff, AZ) is a next-generation balloon-expandable covered stent designed for use with complex AI lesions. The purpose of this study is to evaluate the medium-term outcomes of VIABAHN VBX for such lesions. METHODS: Symptomatic patients who underwent EVT with VIABAHN VBX for an AI lesion from 2018 to 2020 at 7 Japanese centers were reviewed retrospectively. The primary endpoints were primary patency and freedom from target lesion revascularization (TLR). RESULTS: A total of 95 EVT procedures with VIABAHN VBX for AI occlusive lesions were performed in 71 patients. The patients had high rates of dyslipidemia (53%) and chronic kidney disease (61%), and 22% had chronic limb-threatening ischemia (CLTI). The Transatlantic Inter-Society Consensus (TASC Ⅱ) class was A in 12 patients (17%), B in 12 (17%), C in 10 (14%), and D in 37 (52%). Severe calcification (360°) of the treated lesion was present in 31 patients (33%). The median procedure time was 84 (49-158) min, with a technical success rate of 100%. The median follow-up period was 36 (32-43) months. The 3-year primary and secondary patency of VIABAHN VBX were 91% and 99%, the 3-year freedom from TLR was 92%, and the 3-year freedom from major adverse limb event (MALE) was 98%. No limbs required major amputation. Lesion severity (TASC Ⅱ C or D) and severe calcification did not affect the primary patency or freedom from TLR. CONCLUSIONS: Medium-term outcomes after EVT with VIABAHN VBX for AI lesions were acceptable regardless of lesion severity and calcification. These results suggest that VIABAHN VBX may be suitable for AI occlusive lesions with severe anatomical complexity and/or severe calcification.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Maeda K, Kobayashi T, Emura S, et al. Medium-Term Outcomes of Treatment with a VIABAHN VBX Covered Stent for Aortoiliac Occlusive Lesions in Patients with Peripheral Artery Disease. Ann Vasc Surg. 2024. PMID: 38604500. doi:10.1016/j.avsg.2023.12.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。